FRAMINGHAM, MA--(Marketwire - May 16, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the first quarter ended March 31, 2008. The Company reported a net loss of $(685,663), or $(0.04) per share, compared with a net loss of $(1,339,473), or $(0.11) per share, in the prior year. The decreased loss for such period resulted primarily from decreased clinical development expenses related to the clinical trials of IoGen™ and investor relations expenses.
